Angiogenic activity of sera from interstitial lung disease patients in relation to pulmonary function

European Journal of Medical Research

Volumn 15, Issue 2, 2010, Pages 229-234

  Zielonka, Tadeusz Maria ^a   Demkow, U ^a   Radzikowska, E ^b   Bialas, B ^b   Filewska, M ^b   Zycinska, K ^a   Obrowski, M H ^a   Kowalski, J ^b   Wardyn, K A ^a   Skopinska Rozewska, E ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

angiogenesis; diffusing capacity; interstitial lung diseases; lung function tests

Indexed keywords

CARBON MONOXIDE; VASCULOTROPIN A;

ADULT; ALLERGIC PNEUMONITIS; ANGIOGENESIS ASSAY; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BODY PLETHYSMOGRAPHY; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; COLLAGEN DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; LANGERHANS CELL HISTIOCYTOSIS; LUNG COMPLIANCE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; SCLERODERMA; SERUM; SILICOSIS; SPIROMETRY; WEGENER GRANULOMATOSIS; AGED; ANGIOGENESIS; BLOOD; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952277047     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-15-S2-229     Document Type: Article

References (28)

1. Demedts M, Wells AU, Antó JM, Costabel U, Hubbard R, Cullinan P, Slabbynck H, Rizzato G, Poletti V, Verbeken EK, Thomeer MJ, Kokkarinen J, Dalphin JC, Taylor AN: Interstitial lung diseases: an epidemiological overview. Eur Respir J 2001,18(Suppl 32):2S-16S.
2. Wells AU, Rubens MB, du Bois RM, Hansell DM: Functional impairment in fibrosing alveolitis: relationship to reversible disease on thin section computed tomography. Eur Respir J 1997,10(2):280-5. 10.1183/09031936.97.10020280
3. Wagner EJ, Sánchez J, McClintock JY, Jenkins J, Moldobaeva A: Inflammation and ischemia-induced lung angiogenesis. Am J Physiol Lung Cell Mol Physiol 2008,294(2):351-7.
4. Strieter RM: Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 2005,128(5 Suppl 1):526S-32S.
5. Renzoni EA, Walsh DA, Salmon M, Wells AU, Sestini P, Nicholson AG, Veeraraghavan S, Bishop AE, Romanska HM, Pantelidis P, Black CM, du Bois RM: Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003,167(3):438-43. 10.1164/rccm.200202-135OC
6. Tzouvelekis A, Anevlavis S, Bouros D: Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Respir Res 2006, 7: 82. 10.1186/1465-9921-7-82
7. Navarro C, Ruiz V, Gaxiola M, Carrillo G, Selman M: Angiogenesis in hypersensitivity pneumonitis. Arch Physiol Biochem 2003,111(4):365-8.
8. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, Nukiwa T: Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004,169(11):1203-8. 10.1164/rccm.200308-1111OC
9. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S: Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995,32(5):866-9. 10.1016/0190-9622(95)91549-4
10. Zielonka TM, Demkow U, Zycinska K, Filewska M, Bialas B, Kus J, Radzikowska E, Remiszewski P, Szopinski J, Soszka A, Wardyn KA, Skopinska-Rozewska E: Angiogenic activity of sera from interstitial lung disease patients in relation to clinical and radiological changes. Eur J Clin Med 2009,14(Suppl 4):259-64.
11. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report of working party, standardization of lung function tests. Eur Respir J 1993,6(Suppl):5-40.
12. Sidky YA, Auerbach R: Lymphocyte-induced angiogenesis: a quantitative and sensitive assay for the graft-versushost reaction. J Exp Med 1975,141(5):1084-100. 10.1084/jem.141.5.1084
13. Keane MP, Arenberg DA, Lynch JP, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997,159(3):1437-43.
14. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM: Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999,162(10):5511-8.
15. Sekiya M, Ohwada A, Miura K, Takahashi S, Fukuchi Y: Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 2003,181(5):259-65. 10.1007/s00408-003-1028-8
16. Tachihara A, Jin E, Matsuoka T, Ghazizadeh M, Yoshino S, Takemura T, Travis WD, Kawanami O: Critical roles of capillary endothelial cells for alveolar remodelling in nonspecific and usual interstitial pneumonias. J Nippon Med Sch 2006,73(4):203-13. 10.1272/jnms.73.203
17. Tolnay E, Kuhnen C, Voss B, Wiethege T, Müller KM: Expression and localization of vascular endothelial growth factor and its receptor in pulmonary sarcoidosis. Virchows Arch 1998,432(1):61-5. 10.1007/s004280050135
18. Zielonka TM, Demkow U, Bialas B, Filewska M, Zycinska K, Radzikowska E, Szopinski J, Skopinska-Rozewska E: Modulatory effect of sera from sarcoidosis patients on mononuclear cells-induced angiogenesis. J Physiol Pharmacol 2007,58(Suppl 5):753-66.
19. Antoniou KM, Tzouvelekis A, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Rachiotis G, Tzanakis N, Bouros D, Milic-Emili J, Siafakas NM: Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 2006,130(4):982-8. 10.1378/chest.130.4.982
20. Konttinen YT, Mackiewicz Z, Ruuttila P, Ceponis A, Sukura A, Povilenaite D, Hukkanen M, Virtanen I: Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol 2003,22(3):196-202. 10.1007/s10067-003-0698-1
21. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B: Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000,43(4):889-93. 10.1002/1529-0131(200004)43:4<889::AID-ANR21>3.0.CO;2-5
22. Mulligan-Kehoe MJ, Simons M: Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 2007,9(2):173-9. 10.1007/s11926-007-0013-2
23. Senechal B, Elain G, Jeziorski E, Grondin V, Patey-Mariaud de Serre N, Jaubert F, Beldjord K, Lellouch A, Glorion C, Zerah M, Mary P, Barkaoui M, Emile JF, Boccon-Gibod L, Josset P, Debré M, Fischer A, Donadieu J, Geissmann F: Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med 2007,4(8):e253. 10.1371/journal.pmed.0040253
24. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ: Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004,59(4):581-5.
25. Richter AG, McKeown S, Rathinam S, Harper L, Rajesh P, McAuley DF, Heljasvaara R, Thickett DR: Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009,64(8):156-61.
26. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, Strieter RM: CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodelling. Am J Respir Crit Care Med 2005,171(3):261-8.
27. Tabata C, Tabata R, Kadokawa Y, Hisamori S, Takahashi M, Mishima M, Nakano T, Kubo H: Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007,179(1):708-14.
28. Antoniou KM, Pataka A, Bouros D, Siafakas NM: Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2007,20(5):453-61. 10.1016/j.pupt.2006.01.002